Interestingly, we observed an increase in the percentage of effector CD8+Tc in both COVID-19 patient PBMCs and severe BALFs compared to healthy individuals, indicating that the initial differentiation of effector CD8+Tc is not impaired in COVID-19. This evidence concerns the gene CD8A and COVID-19.